Pacheco, J. M., Gao, D., & Camidge, D. R. (2019). Extended follow-up on KEYNOTE-024 suggests significant survival benefit for pembrolizumab in patients with PD-L1 ≥50%, but unanswered questions remain. Ann Transl Med.
Stile di citazione ChicagoPacheco, Jose M., Dexiang Gao, e D. Ross Camidge. "Extended Follow-up On KEYNOTE-024 Suggests Significant Survival Benefit for Pembrolizumab in Patients With PD-L1 ≥50%, but Unanswered Questions Remain." Ann Transl Med 2019.
Citazione MLAPacheco, Jose M., Dexiang Gao, e D. Ross Camidge. "Extended Follow-up On KEYNOTE-024 Suggests Significant Survival Benefit for Pembrolizumab in Patients With PD-L1 ≥50%, but Unanswered Questions Remain." Ann Transl Med 2019.
Attenzione: Queste citazioni potrebbero non essere precise al 100%.